NorthWest Biotherapeutics Inc (NWBO)

[meirluc]

Dstock, While you have presented a lot of interesting evidence that Merck has
been working quietly with NWBO on developing the DCVax-L treatment,
I am quite surprised that Merck's 3 applications for the construction of new
manufacturing facilities (that you just posted) were submitted already throughout
2021. In fact, the application to add manufacturing and office space for vaccines
was dated 2/2/21, barely 4 months after data lock.

Now it is possible that alredy by early 2021 Merck was convinced that DCVax was very efficacious
and Kevin Duffy's work with NWBO may have been one of the catalysts. It is just that the first
positive DCVx-L results were publicized on 5/10/22, 15 months after Merck's application
to add manufacturing and office space for vaccines. For Merck to make such a financial
commitment at that time, they must have already been convinced that DCVax is the golden goose.
This is not impossible if Merck had already some decisively positive information about the main trial
(data beyond the 2018 JTM publication) as well as some preliminary, very positive results from the
combo trials.